Market research
OCX OncoCyte Corp
NASDAQ USD Healthcare
Latest close
As of 17 Jul 2025
Test a moving-average rule with historical data.
Market facts
- Market cap
- 92M
- P/E ratio
- Not available
- Analyst target
- 5.4167
- Dividend yield
- Not available
- Beta
- 0.99
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- Not available
- Market cap
- 92M
- P/E ratio
- Not available
- Analyst target
- 5.4167
- Dividend yield
- Not available
- Beta
- 0.99
About
About OncoCyte Corp
OncoCyte Corporation operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers VitaGraft Kidney, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for kidney transplantation; VitaGraft Liver, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for liver transplantation; and GraftAssure, a dd-cfDNA test that uses droplet digital PCR technology to measure the concentration of dd-cfDNA using 48 predefined SNPs. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Research context
OncoCyte Corp appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Diagnostics & Research
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the OCX discussion.
5 years, 6 months ago
OncoCyte Corporation Common Stock is currently in a long term uptrend where the price is trading 43.1% above its 200 day moving average.
From a valuation standpoint, the stock is 77.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 298.9.
OncoCyte Corporation Common Stock's total revenue rose by inf% to $503K since the same quarter in the previous year.
Its net income has increased by 20.7% to $-6M since the same quarter in the previous year.
Finally, its free cash flow fell by 1.8% to $-6M since the same quarter in the previous year.
Based on the above factors, OncoCyte Corporation Common Stock gets an overall score of 4/5.